Table 2 Patient and tumor characteristics
From: Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
Patient cohort | Total n = 77 |
|---|---|
Gender, n (%) | |
 Male | 53 (69) |
 Female | 24 (31) |
Age at diagnosis, years | |
 Median (range) | 62 (40–76) |
Age at metastatic disease, years | |
 Median (range) | 64,5 (40–77) |
Histologictype, n (%) | |
 Clear cell | 68 (88) |
 Papillary | 2 (3) |
 Mixed phenotype | 2 (3) |
 Unknown | 5 (6) |
Local disease at diagnosis, n (%) | 36 (47) |
Metastatic disease at diagnosis, n (%) | 41 (53) |
Time to metastasis, years | |
 Median (range) | 2 (0–18) |
Metastasis during first year, n (%) | 14 (39) |
Metastasis after first year, n (%) | 22 (61) |
Alive, n (%) | 16 (21) |
Dead, n (%) | 61 (79) |